Wanhua Chemical Group Co.Ltd(600309) : the listing price of pure MDI in China increased in March; Aba Chemicals Corporation(300261) performance express: net profit in 2021 increased by 12.13% year-on-year
selected Announcements:
Wanhua Chemical Group Co.Ltd(600309) : the listing price of pure MDI in China increased by
Wanhua Chemical Group Co.Ltd(600309) (600309) announced on February 25 that since March 2022, Wanhua Chemical Group Co.Ltd(600309) China's aggregate MDI listing price is 22800 yuan / ton (no change compared with February); The listing price of pure MDI is 26800 yuan / ton (3000 yuan / ton higher than the price in February).
Aba Chemicals Corporation(300261) performance express: net profit in 2021 increased by 12.13% year-on-year
Aba Chemicals Corporation(300261) (300261) released the performance express on February 25. The operating revenue in 2021 was 2.085 billion yuan, a year-on-year increase of 4.09%; The net profit attributable to the parent company was 181 million yuan, a year-on-year increase of 12.13%; The basic earnings per share is 0.1891 yuan.
National Silicon Industry Group Co.Ltd(688126) fixed increase result: the large fund phase II was allocated about 1.5 billion yuan
National Silicon Industry Group Co.Ltd(688126) (688126) disclosed the fixed increase results. The total amount raised was about 5 billion yuan, of which the second phase of the large fund was allocated about 1.5 billion yuan.
China Evergrande: signed cooperation agreements with Everbright trust and Minmetals trust
China Evergrande announced that on February 25, the Group signed a cooperation agreement with Everbright trust and Minmetals trust on the sale of the group's relevant equity in four projects to them. The trust institution will take over the operation and management of the project company, invest funds in the project company to ensure the subsequent development and construction of the project and guarantee the delivery of the building, and the group has the right to repurchase equity. Through this cooperation with trust institutions, the group can recover part of the early-stage investment of the project of about RMB 1.95 billion and resolve the debt involved in the project of about RMB 7.01 billion. The recovered investment has a positive impact on the guaranteed delivery and debt resolution of other projects of the group.
Shanghai Medicilon Inc(688202) performance express: net profit in 2021 increased by 117.93% year-on-year
Shanghai Medicilon Inc(688202) (688202) released the performance express on February 25. The operating revenue in 2021 was 1.167 billion yuan, a year-on-year increase of 75.27%; The net profit attributable to the parent company was 282 million yuan, a year-on-year increase of 117.93%; The basic earnings per share is 4.55 yuan. During the reporting period, benefiting from the increasing encouragement of national policies for the pharmaceutical industry and the continuous improvement of pharmaceutical enterprises' investment in innovative drug R & D, while optimizing the business structure, the company firmly grasped the development opportunity of preclinical cro market, and the customer development ability and order acceptance ability were improved simultaneously.
Harbin Jiuzhou Group Co.Ltd(300040) performance express: the net profit in 2021 was 184 million yuan, with a year-on-year increase of 162.52%
Harbin Jiuzhou Group Co.Ltd(300040) (300040) released the performance express on February 25. The operating revenue in 2021 was 1.398 billion yuan, a year-on-year increase of 9.23%; The net profit attributable to the parent company was 184 million yuan, a year-on-year increase of 162.52%; The basic earnings per share is 0.33 yuan. The performance growth was mainly due to the growth of the company's renewable energy business, the reversal of credit impairment losses caused by the inclusion of Ronghe power investment No. 1 (Jiaxing) venture capital partnership (limited partnership) into the scope of the company's merger, and the increase of profits due to the sale of some equity of Merris comprehensive smart energy project.
Zhejiang Orient Gene Biotech Co.Ltd(688298) performance express: the net profit in 2021 was 4.777 billion yuan, with a year-on-year increase of 184.8%
Zhejiang Orient Gene Biotech Co.Ltd(688298) (688298) released the performance express on February 25. The operating revenue in 2021 was 10.032 billion yuan, a year-on-year increase of 207.22%; The net profit attributable to the parent company was 4.777 billion yuan, a year-on-year increase of 184.80%; The basic earnings per share is 39.81 yuan. In 2021, New Coronavirus rapid detection reagent (including family self testing) continued to be put into the epidemic prevention business. The sales performance of the products in the European market continued to increase significantly, and the routine diagnostic reagents and diagnostic instruments business maintained steady development, which contributed to a substantial increase in operating performance in 2021.
Ningbo Energy Group Co.Ltd(600982) : Recently, preliminary negotiations are being held with Fenghua district government on pumped storage projects
Ningbo Energy Group Co.Ltd(600982) (600982) the announcement of changes was issued on February 25. According to the company's self-examination, the company is currently conducting preliminary negotiations with the people's Government of Fenghua District, Ningbo and Power Construction Corporation Of China Ltd(Powerchina Ltd)(601669) Group East China survey, design and Research Institute Co., Ltd. on the cooperation of pumped storage projects in Fenghua area. The contents of the tripartite negotiations are not legally binding, and there are major uncertainties in the implementation of the project.
Asahi biological performance express: the net profit in 2021 was 739 million yuan, with a year-on-year increase of 13.82%
An Xu Biology (688075) released its performance express on February 25. The operating revenue in 2021 was 1.589 billion yuan, a year-on-year increase of 32.47%; The net profit attributable to the parent company was 739 million yuan, a year-on-year increase of 13.82%; The basic earnings per share is 15.62 yuan. During the reporting period, the company's high-quality covid-19 testing product quality was recognized by the market and customers, the operating revenue and net profit increased rapidly, and the sales scale continued to expand.
Guangdong Leadyo Ic Testing Co.Ltd(688135) performance express: net profit in 2021 increased by 114.12% year-on-year
Guangdong Leadyo Ic Testing Co.Ltd(688135) (688135) released the performance express on February 25. The operating revenue in 2021 was 398 million yuan, a year-on-year increase of 57.44%; The net profit attributable to the parent company was 111 million yuan, a year-on-year increase of 114.12%; The basic earnings per share is 0.82 yuan. With the gradual implementation of raised investment projects, the testing capacity is gradually released and benefits are generated. The company's chip testing in 5g communication, industrial control, biometrics, MCU, aiot and other fields maintained rapid growth in 2021.
Cambricon Technologies Corporation Limited(688256) performance express: loss of 847 million yuan in 2021
Cambricon Technologies Corporation Limited(688256) (688256) released the performance express on February 25. The operating revenue in 2021 was 721 million yuan, a year-on-year increase of 57.12%; The net profit attributable to the parent company lost 847 million yuan, and the net profit attributable to the parent company lost 435 million yuan in the same period of last year; The basic earnings per share is -2.12 yuan. During the reporting period, the edge product line mlu220 chip and accelerator card landed in a number of head enterprises, achieved large-scale sales of nearly one million pieces during the reporting period, and the income of the edge product line achieved a breakthrough growth over the same period of last year. Relying on the benchmarking effect and excellent reputation of the company's early projects, the company won the bid for the infrastructure construction project of Intelligent Computing Center in Kunshan, Jiangsu, and the revenue of cluster business increased significantly compared with the same period of last year.
Bloomage Biotechnology Corporation Limited(688363) performance express: net profit in 2021 increased by 21.13% year-on-year
Bloomage Biotechnology Corporation Limited(688363) (688363) released the performance express on February 25. The operating revenue in 2021 was 4.948 billion yuan, a year-on-year increase of 87.93%; The net profit attributable to the parent company was 782 million yuan, a year-on-year increase of 21.13%; The basic earnings per share is 1.63 yuan. During the reporting period, the company steadily promoted the "four-wheel drive" business layout, the raw material business and medical terminal business grew steadily, the functional skin care business continued to maintain rapid growth, and the functional food business got a good start.
\u3000\u3000
